45 related articles for article (PubMed ID: 36301154)
1. Lipid-mediated delivery of CD47 siRNA aids JQ1 in ensuring simultaneous downregulation of PD-L1 and CD47 and improves antitumor immunotherapy efficacy.
Li Y; Meng X; Chen G; Hou Y; Wu X; Wang J; Cong X; Mao K; Wu C; Chen H; Sun X; Zhou J; Wang Y; Yang YG; Sun T
Biomater Sci; 2022 Nov; 10(23):6755-6767. PubMed ID: 36301154
[TBL] [Abstract][Full Text] [Related]
2. An "eat me" combinatory nano-formulation for systemic immunotherapy of solid tumors.
Abdel-Bar HM; Walters AA; Lim Y; Rouatbi N; Qin Y; Gheidari F; Han S; Osman R; Wang JT; Al-Jamal KT
Theranostics; 2021; 11(18):8738-8754. PubMed ID: 34522209
[No Abstract] [Full Text] [Related]
3. Design of a novel chimeric peptide via dual blockade of CD47/SIRPα and PD-1/PD-L1 for cancer immunotherapy.
Hu Z; Li W; Chen S; Chen D; Xu R; Zheng D; Yang X; Li S; Zhou X; Niu X; Xiao Y; He Z; Li H; Liu J; Sui X; Gao Y
Sci China Life Sci; 2023 Oct; 66(10):2310-2328. PubMed ID: 37115491
[TBL] [Abstract][Full Text] [Related]
4. Nanoassembly of doxorubicin-conjugated polyphosphoester and siRNA simultaneously elicited macrophage- and T cell- mediated anticancer immune response for cancer therapy.
Li D; Cao Z; Chen C; Li H; He S; Hou X; Liang M; Yang X; Wang J
Biomaterials; 2023 Nov; 302():122339. PubMed ID: 37778054
[TBL] [Abstract][Full Text] [Related]
5. Blockade of the Immune Checkpoint CD47 by TTI-621 Potentiates the Response to Anti-PD-L1 in Cutaneous T-Cell Lymphoma.
Han Z; Wu X; Qin H; Yuan YC; Zain J; Smith DL; Akilov OE; Rosen ST; Feng M; Querfeld C
J Invest Dermatol; 2023 Aug; 143(8):1569-1578.e5. PubMed ID: 36863449
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic virus M1 functions as a bifunctional checkpoint inhibitor to enhance the antitumor activity of DC vaccine.
Dan J; Cai J; Zhong Y; Wang C; Huang S; Zeng Y; Fan Z; Xu C; Hu L; Zhang J; Hu J; Liu Y; Su X; Zhu W; Yan G; Liang J; Lin Y
Cell Rep Med; 2023 Oct; 4(10):101229. PubMed ID: 37820722
[TBL] [Abstract][Full Text] [Related]
7. Engineering high-affinity dual targeting cellular nanovesicles for optimised cancer immunotherapy.
Zhang L; Zhao X; Niu Y; Ma X; Yuan W; Ma J
J Extracell Vesicles; 2023 Nov; 12(11):e12379. PubMed ID: 37974395
[TBL] [Abstract][Full Text] [Related]
8. Microfluidics-Enabled Nanovesicle Delivers CD47/PD-L1 Antibodies to Enhance Antitumor Immunity and Reduce Immunotoxicity in Lung Adenocarcinoma.
Su Z; Dong S; Chen Y; Huang T; Qin B; Yang Q; Jiang X; Zou C
Adv Sci (Weinh); 2023 Jul; 10(20):e2206213. PubMed ID: 37132609
[TBL] [Abstract][Full Text] [Related]
9. B7-H3 drives immunosuppression and Co-targeting with CD47 is a new therapeutic strategy in β-catenin activated melanomas.
Hsu M; Martin TC; Vyas NS; Desman G; Mendelson K; Horst B; Parsons RE; Celebi JT
Pigment Cell Melanoma Res; 2023 Sep; 36(5):407-415. PubMed ID: 37086018
[TBL] [Abstract][Full Text] [Related]
10. STING agonist-loaded, CD47/PD-L1-targeting nanoparticles potentiate antitumor immunity and radiotherapy for glioblastoma.
Zhang P; Rashidi A; Zhao J; Silvers C; Wang H; Castro B; Ellingwood A; Han Y; Lopez-Rosas A; Zannikou M; Dmello C; Levine R; Xiao T; Cordero A; Sonabend AM; Balyasnikova IV; Lee-Chang C; Miska J; Lesniak MS
Nat Commun; 2023 Mar; 14(1):1610. PubMed ID: 36959214
[TBL] [Abstract][Full Text] [Related]
11. Inducing Tumor Suppressive Microenvironments through Genome Edited CD47
Jayaraman Rukmini S; Bi H; Sen P; Everhart B; Jin S; Ye K
Sci Rep; 2019 Dec; 9(1):20057. PubMed ID: 31882679
[TBL] [Abstract][Full Text] [Related]
12. A Biomimetic Nanogel System Restores Macrophage Phagocytosis for Magnetic Resonance Imaging-Guided Synergistic Chemoimmunotherapy of Breast Cancer.
Li L; Gao Y; Zhang Y; Yang R; Ouyang Z; Guo R; Yu H; Shi X; Cao X
Adv Healthc Mater; 2023 Oct; 12(26):e2300967. PubMed ID: 37470683
[TBL] [Abstract][Full Text] [Related]
13. CD47 and PD-L1 overexpression in proliferating human hepatocytes attenuated immune responses and ameliorated acute liver injury in mice.
Ma C; Cao H; Sun Z; Deng Q; Liu W; Xin Y; Qiao S; Cen J; Shu Y; Qi K; Han L; Zhang L; Pan G
Am J Transplant; 2023 Dec; 23(12):1832-1844. PubMed ID: 37532180
[TBL] [Abstract][Full Text] [Related]
14. Nanosystem Delivers Senescence Activators and Immunomodulators to Combat Liver Cancer.
Gong K; Jiao J; Wu Z; Wang Q; Liao J; Duan Y; Lin J; Yu J; Sun Y; Zhang Y; Duan Y
Adv Sci (Weinh); 2024 May; 11(20):e2308310. PubMed ID: 38520730
[TBL] [Abstract][Full Text] [Related]
15. Hydrophobization of Ribonucleic Acids for Facile Systemic Delivery and Multifaceted Cancer Immunotherapy.
Zhang Y; Chen C; Su M; Wang J; Li C; Yang X
Nano Lett; 2024 Jan; 24(4):1376-1384. PubMed ID: 38232332
[TBL] [Abstract][Full Text] [Related]
16. An optimized ionizable cationic lipid for brain tumor-targeted siRNA delivery and glioblastoma immunotherapy.
Liu S; Liu J; Li H; Mao K; Wang H; Meng X; Wang J; Wu C; Chen H; Wang X; Cong X; Hou Y; Wang Y; Wang M; Yang YG; Sun T
Biomaterials; 2022 Aug; 287():121645. PubMed ID: 35779480
[TBL] [Abstract][Full Text] [Related]
17. Dual blockage of both PD-L1 and CD47 enhances the therapeutic effect of oxaliplatin and FOLFOX in CT-26 mice tumor model.
Alimohammadi R; Mahmoodi Chalbatani G; Alimohammadi M; Ghaffari-Nazari H; Rahimi A; Mortaz E; Mossafa N; Boon L; Jalali SA
Sci Rep; 2023 Feb; 13(1):2472. PubMed ID: 36774400
[TBL] [Abstract][Full Text] [Related]
18. Blockade of dual immune checkpoint inhibitory signals with a CD47/PD-L1 bispecific antibody for cancer treatment.
Wang R; Zhang C; Cao Y; Wang J; Jiao S; Zhang J; Wang M; Tang P; Ouyang Z; Liang W; Mao Y; Wang A; Li G; Zhang J; Wang M; Wang S; Gui X
Theranostics; 2023; 13(1):148-160. PubMed ID: 36593962
[No Abstract] [Full Text] [Related]
19. Understanding the regulation of "Don't Eat-Me" signals by inflammatory signaling pathways in the tumor microenvironment for more effective therapy.
Karizak AZ; Salmasi Z; Gheibihayat SM; Asadi M; Ghasemi Y; Tajbakhsh A; Savardashtaki A
J Cancer Res Clin Oncol; 2023 Jan; 149(1):511-529. PubMed ID: 36342520
[TBL] [Abstract][Full Text] [Related]
20. CD47: The Next Frontier in Immune Checkpoint Blockade for Non-Small Cell Lung Cancer.
Lau APY; Khavkine Binstock SS; Thu KL
Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
